Welcome to our dedicated page for Enanta Pharmaceuticals SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enanta Pharmaceuticals, Inc. (ENTA) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered securities documents. As a Nasdaq Global Select Market issuer, Enanta uses these filings to report material events, financial results, capital markets transactions, and key clinical and corporate developments related to its small molecule virology and immunology programs.
Investors can review Form 8-K filings in which Enanta reports quarterly and annual financial results, including royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET and commentary on cash, cash equivalents and marketable securities. Other 8-Ks describe public offerings of common stock, such as underwriting agreements, expected net proceeds, and closing conditions for upsized offerings used to fund clinical trials, research, and general corporate purposes.
Filings also capture clinical and R&D milestones, for example the disclosure of positive topline data from the Phase 2b high-risk adult RSV study of zelicapavir, including symptom resolution, virology endpoints, and safety outcomes. Regulation FD 8-Ks may furnish slide presentations or press releases detailing these results. Additional 8-Ks document corporate governance and management changes, such as interim appointments to principal financial officer and principal accounting officer roles.
Enanta’s SEC reports further reference legal and intellectual property matters, including its announcement of a patent infringement suit in the Unified Patent Court of the European Union regarding European Patent No. EP 4 051 265 and Pfizer’s Paxlovid. Through Stock Titan, users can access these filings as they are posted to EDGAR, while AI-powered summaries help explain the implications of complex documents like 8-Ks, registration statements, and related exhibits. This allows readers to quickly understand how financings, clinical data disclosures, and legal actions may relate to Enanta’s RSV and immunology pipelines and its royalty-funded business model.
Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported equity compensation transactions in Enanta common stock. On February 12, 2026, she acquired 1,575 shares through performance share units that vested based on 2024-2025 research and development milestones, as determined by the Compensation Committee. She also acquired 4,987 shares from a relative total stockholder return unit award tied to Enanta’s stock performance versus the Nasdaq Biotech Index over matching 60-day periods two years apart. To cover withholding taxes from these awards, 3,257 shares were automatically forfeited at a price of $14.25 per share. Following these transactions, she directly held 33,925 shares of Enanta common stock.
Enanta Pharmaceuticals Chief Medical Officer Scott T. Rottinghaus reported equity award activity in company stock. On February 12, 2026, he acquired 1,650 shares of common stock at
On the same date, he acquired an additional 5,225 shares at
Enanta Pharmaceuticals’ Chief Scientific Officer Or Yat Sun reported equity compensation activity. On February 12, 2026, Sun acquired 1,650 shares of common stock from performance share units tied to 2024–2025 R&D milestones and 5,225 shares from a relative total stockholder return unit award, both at $0 per share. On the same date, 3,413 shares were automatically forfeited at $14.25 per share to cover withholding taxes from settlement of these awards. Following these transactions, Sun directly owned 374,854 common shares.
Enanta Pharmaceuticals President and CEO Jay R. Luly, who is also a director, reported equity award activity in Enanta common stock. On February 12, 2026, he acquired 4,800 shares through performance share units tied to 2024-2025 R&D milestones and 15,200 shares from a relative total stockholder return unit award, both at no cash price. On the same date, 6,155 shares were automatically withheld and forfeited at $14.25 per share to cover tax obligations from these vestings. After these transactions, he directly beneficially owned 871,871 shares of Enanta common stock.
Deep Track Capital and affiliates report a 6.78% stake in Enanta Pharmaceuticals Inc. The group, including Deep Track Biotechnology Master Fund and David Kroin, beneficially owns 1,956,867 shares of Enanta common stock, with shared voting and dispositive power over all reported shares.
The ownership percentage is based on 28,862,601 Enanta common shares outstanding as of November 4, 2025, as referenced from the company’s Form 10-K. The reporting persons certify the shares are not held for the purpose of changing or influencing control of Enanta.
Enanta Pharmaceuticals, Inc. has filed a shelf registration statement on Form S-3 to offer and sell up to
Enanta is a biotechnology company focused on small-molecule drugs for virology, including RSV, SARS‑CoV‑2, HCV and HBV, and for immunology indications such as atopic dermatitis, urticarias, asthma, COPD, CRSwNP and prurigo nodularis. Net proceeds from any offerings are intended for general corporate purposes, including R&D, commercialization, manufacturing, possible acquisitions and potential repayment or repurchase of future indebtedness or capital stock.
Enanta Pharmaceuticals reported royalty revenue of $18.6 million for the quarter ended December 31, 2025, up from $17.0 million a year earlier, driven by higher HCV sales of MAVYRET/MAVIRET from AbbVie.
Research and development expenses fell to $20.9 million from $27.7 million, mainly as RSV trials wound down, while general and administrative expenses decreased to $9.0 million from $12.8 million due to lower stock-based compensation and legal costs. Net loss narrowed to $11.9 million from $22.3 million, or $0.42 per share versus $1.05 per share.
Enanta closed an October 2025 public offering of 7.5 million shares at $10.00, generating $69.9 million in net proceeds. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $241.9 million, which the company believes will fund operations into fiscal 2029 while it advances RSV antivirals and multiple immunology programs.
Enanta Pharmaceuticals reported a narrower net loss for its fiscal first quarter ended December 31, 2025 while advancing its RSV and immunology pipelines. Revenue rose to $18.6 million from $17.0 million, driven by higher royalties on AbbVie’s MAVYRET®/MAVIRET® hepatitis C treatment.
Research and development expense fell to $20.9 million from $27.7 million and general and administrative expense declined to $9.0 million from $12.8 million, reflecting lower clinical, stock-based compensation and legal costs. Net loss improved to $11.9 million, or $0.42 per diluted share, from $22.3 million, or $1.05 per diluted share.
Enanta ended the quarter with $241.9 million in cash, cash equivalents and marketable securities and expects this, plus its retained portion of future royalty revenue, to fund operations into fiscal 2029. The company is conducting Phase 3 enabling work for RSV candidate zelicapavir, progressing RSV drug EDP-323, and advancing three immunology programs, including KIT inhibitor EDP-978 and STAT6 inhibitor EPS-3903, with multiple planned IND filings and data milestones in 2026.
Enanta Pharmaceuticals Inc. received an amended ownership report from Farallon-affiliated investors. The Schedule 13G/A (Amendment No. 7) shows multiple Farallon funds and related entities collectively reporting beneficial ownership positions in Enanta’s common stock.
The largest reported position is by Farallon Partners, L.L.C., which is listed with 2,640,779 Shares, representing 9.1% of the class. Several Farallon Individual Reporting Persons, including Joshua J. Dapice and others, are each reported as beneficial owners of 2,816,862 Shares, or 9.8% of the class, through their roles over the Farallon funds.
The amendment discloses governance changes in the Farallon General Partner structure. Effective January 1, 2026, Avner A. Husen became a member/manager of the relevant general partners and may be deemed a beneficial owner. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased those roles and may no longer be deemed beneficial owners. The group certifies the holdings are not for the purpose of changing or influencing control, and the filing is made under Rule 13d-1(c).